IgA Nephropathy Clinical Trials Pipeline Analysis: 30+ Companies are Working to Improve the Treatment Space | DelveInsight
14 déc. 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- IgA Nephropathy Clinical Trials Pipeline Analysis: 30+ Companies are Working to Improve the Treatment Space | DelveInsight DelveInsight’s IgA...
Travere Therapeutics Reports Third Quarter 2022 Financial Results
27 oct. 2022 16h01 HE
|
Travere Therapeutics, Inc.
EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023 New PDUFA target action date for...
Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
24 oct. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the Company will present two posters at the upcoming American Society...
Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
22 sept. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, Chief Executive Officer, will participate in...
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy
06 sept. 2022 16h01 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's...
Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results
11 août 2022 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Received FDA clearance of IND application for Phase 2 trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients First patient dosed in Phase 1b trial evaluating...
Travere Therapeutics Provides Regulatory Updates on its Development Programs
03 août 2022 16h05 HE
|
Travere Therapeutics, Inc.
PDUFA target action date for NDA for sparsentan in IgAN on-track for November 17, 2022 Company to utilize traditional approval process for sparsentan in FSGS following completion of the pivotal Phase...
Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation
18 juil. 2022 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 juin 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation
09 juin 2022 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...